Assessment of the Skin-Concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

This study has been terminated.

( After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome. )

Study NCT00633997 Information provided by Novartis

First Received: March 4, 2008 Last Updated: June 16, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Diabetes Mellitus

More general conditions related to this trial

Interventions listed in this trial

Vildagliptin

More general drug interventions related to this trial

Sponsors listed in this trial

Novartis